NEW YORK, Sept. 1 (GenomeWeb News) - The National Cancer Institute has purchased genotyping instrumentation from Illumina for its Advanced Technology Center core genotyping facility in Gaithersburg, Md., the company said today.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
